MedImmune Announces Preliminary Results for 2007 First Quarter
2007年4月9日 - 10:00PM
PRニュース・ワイアー (英語)
Company Invites Investors to Participate in First-Quarter 2007
Earnings Conference Call on May 3, 2007 GAITHERSBURG, Md., April 9
/PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced
today that it anticipates its first-quarter diluted earnings per
share (EPS), excluding share-based compensation expense, to be in
the range of $0.62 to $0.67, as compared to $0.23 in diluted EPS in
the 2006 first quarter, excluding share-based compensation. This
nearly three-fold increase in expected EPS is due to an estimated
11-to-12 percent increase in total revenues and a greater than
two-fold increase in net income margin. The company also stated
that for the 2007 first quarter, it expects domestic and worldwide
net sales growth of approximately 9-to-10 percent for Synagis(R)
(palivizumab) over the same quarter in 2006. MedImmune anticipates
reporting its final 2007 first-quarter financial results on May 3,
2007 before the opening of the U.S. financial markets. This allows
MedImmune to report royalties and milestones earned on its HPV
vaccine technology in the same quarter as the related vaccine sales
are reported by Merck and GlaxoSmithKline. The company is also
planning to host a conference call and live audio webcast at 8:00
a.m. eastern time following the announcement. During the conference
call, MedImmune's management will discuss the financial results and
other business. The press release and the live webcast can be
accessed by going to the Investor Relations section of the
MedImmune website at http://www.medimmune.com/. An archived version
of the call will be available at the same address for one week
after the live webcast. About MedImmune, Inc. MedImmune strives to
provide better medicines to patients, new medical options for
physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help
people live better lives, the company is focused on the areas of
infectious disease, cancer and inflammatory diseases. With more
than 2,500 employees worldwide, MedImmune is headquartered in
Maryland. For more information, visit the company's website at
http://www.medimmune.com/. This announcement contains
forward-looking statements including that the company expects to
disseminate financial information for the first quarter of 2007.
Such statements reflect management's current views and are based on
certain assumptions, including but not limited to, completion of
the company's quarter-end closing procedures and completion of
certain quarter-end review procedures. There can be no assurance
that such procedures will be completed in the timeframe allotted or
for those reasons or any others, that the company will not choose
to disseminate such financial information on a different date
and/or time. DATASOURCE: MedImmune, Inc. CONTACT: investors, Peter
Vozzo, +1-301-398-4358; media, Jamie Lacey, +1-301-398-4035 Web
site: http://www.medimmune.com/
Copyright
Medimmune (NASDAQ:MEDI)
過去 株価チャート
から 11 2024 まで 12 2024
Medimmune (NASDAQ:MEDI)
過去 株価チャート
から 12 2023 まで 12 2024
Real-Time news about Medimmune (MM) (ナスダック市場): 0 recent articles
その他のMedimmune (MM)ニュース記事